• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用双 CRISPR/Cas9 方法深入了解 LRP1B 在胶质母细胞瘤中的作用。

Using a Dual CRISPR/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma.

机构信息

i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.

Cancer Signaling and Metabolism Group, IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Rua Alfredo Allen 208, 4169-007 Porto, Portugal.

出版信息

Int J Mol Sci. 2023 Jul 10;24(14):11285. doi: 10.3390/ijms241411285.

DOI:10.3390/ijms241411285
PMID:37511044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10379115/
Abstract

remains one of the most altered genes in cancer, although its relevance in cancer biology is still unclear. Recent advances in gene editing techniques, particularly CRISPR/Cas9 systems, offer new opportunities to evaluate the function of large genes, such as . Using a dual sgRNA CRISPR/Cas9 gene editing approach, this study aimed to assess the impact of disrupting in glioblastoma cell biology. Four sgRNAs were designed for the dual targeting of two exons (1 and 85). The U87 glioblastoma (GB) cell line was transfected with CRISPR/Cas9 PX459 vectors. To assess -gene-induced alterations and expression, PCR, Sanger DNA sequencing, and qRT-PCR were carried out. Three clones (clones B9, E6, and H7) were further evaluated. All clones presented altered cellular morphology, increased cellular and nuclear size, and changes in ploidy. Two clones (E6 and H7) showed a significant decrease in cell growth, both in vitro and in the in vivo CAM assay. Proteomic analysis of the clones' secretome identified differentially expressed proteins that had not been previously associated with alterations. This study demonstrates that the dual sgRNA CRISPR/Cas9 strategy can effectively edit in GB cells, providing new insights into the impact of deletions in GBM biology.

摘要

仍然是癌症中改变最多的基因之一,尽管其在癌症生物学中的相关性仍不清楚。基因编辑技术的最新进展,特别是 CRISPR/Cas9 系统,为评估大型基因的功能提供了新的机会,如 。本研究采用双 sgRNA CRISPR/Cas9 基因编辑方法,旨在评估破坏 对神经胶质瘤细胞生物学的影响。设计了四个 sgRNA 用于靶向两个 外显子(1 和 85)的双重靶向。U87 神经胶质瘤(GB)细胞系用 CRISPR/Cas9 PX459 载体转染。为了评估 -基因诱导的改变和表达,进行了 PCR、Sanger DNA 测序和 qRT-PCR。进一步评估了三个克隆(克隆 B9、E6 和 H7)。所有克隆均呈现出改变的细胞形态、增大的细胞和核大小以及倍性变化。两个克隆(E6 和 H7)显示出体外和体内 CAM 测定中细胞生长的显著下降。克隆分泌组的蛋白质组学分析鉴定出以前与 改变无关的差异表达蛋白。本研究表明,双 sgRNA CRISPR/Cas9 策略可有效编辑 GB 细胞中的 ,为 缺失对 GBM 生物学的影响提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/63d75eafae68/ijms-24-11285-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/9ac357d3ee7d/ijms-24-11285-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/255b32c94ed8/ijms-24-11285-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/87f2c50cf1c0/ijms-24-11285-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/575bf86348c9/ijms-24-11285-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/4da51ab78f46/ijms-24-11285-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/9c38b383cbd1/ijms-24-11285-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/e99903dbee10/ijms-24-11285-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/21db5f14bd9d/ijms-24-11285-g008a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/63d75eafae68/ijms-24-11285-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/9ac357d3ee7d/ijms-24-11285-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/255b32c94ed8/ijms-24-11285-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/87f2c50cf1c0/ijms-24-11285-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/575bf86348c9/ijms-24-11285-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/4da51ab78f46/ijms-24-11285-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/9c38b383cbd1/ijms-24-11285-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/e99903dbee10/ijms-24-11285-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/21db5f14bd9d/ijms-24-11285-g008a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ee8/10379115/63d75eafae68/ijms-24-11285-g009.jpg

相似文献

1
Using a Dual CRISPR/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma.采用双 CRISPR/Cas9 方法深入了解 LRP1B 在胶质母细胞瘤中的作用。
Int J Mol Sci. 2023 Jul 10;24(14):11285. doi: 10.3390/ijms241411285.
2
Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.CRISPR/Cas9 双 sgRNA 敲除人 U87 神经胶质瘤肿瘤细胞中的 PD-L1 抑制增殖、侵袭和肿瘤相关巨噬细胞极化。
Sci Rep. 2022 Feb 14;12(1):2417. doi: 10.1038/s41598-022-06430-1.
3
A simple and highly efficient method for multi-allelic CRISPR-Cas9 editing in primary cell cultures.一种在原代细胞培养物中进行多位点 CRISPR-Cas9 编辑的简单而高效的方法。
Cancer Rep (Hoboken). 2020 Oct;3(5):e1269. doi: 10.1002/cnr2.1269. Epub 2020 Jul 28.
4
Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.CRISPR-Cas9 技术在多形性胶质母细胞瘤基因组编辑中的应用。
Cells. 2021 Sep 7;10(9):2342. doi: 10.3390/cells10092342.
5
Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy.血脑屏障穿透型单 CRISPR-Cas9 纳米胶囊用于胶质母细胞瘤的有效和安全基因治疗。
Sci Adv. 2022 Apr 22;8(16):eabm8011. doi: 10.1126/sciadv.abm8011. Epub 2022 Apr 20.
6
[ADRB2 Gene Knockout in Human Primary T Cells by Multiple sgRNAs Construced using CRISPR/Cas9 Technology].利用CRISPR/Cas9技术构建多个sgRNA对人原代T细胞进行ADRB2基因敲除
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Oct;27(5):1682-1690. doi: 10.19746/j.cnki.issn.1009-2137.2019.05.050.
7
Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy.脑靶向 CRISPR/Cas9 纳米医学用于有效的脑胶质母细胞瘤治疗。
J Control Release. 2022 Nov;351:739-751. doi: 10.1016/j.jconrel.2022.09.046. Epub 2022 Oct 8.
8
Conditional editing of the genome using single transcripts expressing Cas9 and sgRNA.利用表达 Cas9 和 sgRNA 的单转录本对基因组进行条件编辑。
Yi Chuan. 2023 Jul 20;45(7):593-601. doi: 10.16288/j.yczz.23-099.
9
RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells.RNA 脂质纳米颗粒作为有效的体内 CRISPR-Cas9 基因编辑工具,用于神经胶质瘤癌症干细胞中的治疗靶点验证。
J Control Release. 2024 Nov;375:776-787. doi: 10.1016/j.jconrel.2024.09.019. Epub 2024 Oct 2.
10
Single Molecule FRET Analysis of CRISPR Cas9 Single Guide RNA Folding Dynamics.单分子 FRET 分析 CRISPR Cas9 单指导 RNA 折叠动力学。
J Phys Chem B. 2023 Jan 12;127(1):45-51. doi: 10.1021/acs.jpcb.2c05428. Epub 2022 Dec 23.

引用本文的文献

1
Mutational analysis of primary and advanced chordoma tissue using next-generation sequencing.使用下一代测序技术对原发性和晚期脊索瘤组织进行突变分析。
Cancer. 2025 Aug 15;131(16):e70033. doi: 10.1002/cncr.70033.
2
Advanced nanotheranostic approaches for targeted glioblastoma treatment: a synergistic fusion of CRISPR-Cas gene editing, AI-driven tumor profiling, and BBB-modulation.用于靶向胶质母细胞瘤治疗的先进纳米诊疗方法:CRISPR-Cas基因编辑、人工智能驱动的肿瘤分析和血脑屏障调节的协同融合。
Med Oncol. 2025 Aug 7;42(9):413. doi: 10.1007/s12032-025-02944-6.
3
Impact of Dietary Salicylates on Iron, Zinc, and Copper Status in Preeclampsia Model Rats Induced by L-NAME.

本文引用的文献

1
High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma.高VEGFA表达与复发性胶质母细胞瘤贝伐单抗治疗后无进展生存期的改善相关。
Cancers (Basel). 2023 Apr 7;15(8):2196. doi: 10.3390/cancers15082196.
2
Prime editing: advances and therapeutic applications.碱基编辑:进展与治疗应用。
Trends Biotechnol. 2023 Aug;41(8):1000-1012. doi: 10.1016/j.tibtech.2023.03.004. Epub 2023 Mar 30.
3
Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
膳食水杨酸盐对L-NAME诱导的子痫前期模型大鼠铁、锌和铜状态的影响
Biol Trace Elem Res. 2025 Aug 7. doi: 10.1007/s12011-025-04772-1.
4
LRP1 Mediates Endocytosis Activity and Is a Potential Therapeutic Target in Osteoarthritis.低密度脂蛋白受体相关蛋白1介导内吞活性,是骨关节炎的一个潜在治疗靶点。
Orthop Surg. 2025 Jun;17(6):1604-1619. doi: 10.1111/os.70035. Epub 2025 Apr 2.
5
Molecular characteristics and cancer immunity of LRP1B and its relationship with the Hedgehog signaling pathway in colorectal cancer.LRP1B在结直肠癌中的分子特征、癌症免疫及其与刺猬信号通路的关系
Front Immunol. 2025 Mar 18;16:1567102. doi: 10.3389/fimmu.2025.1567102. eCollection 2025.
6
Nanostructured lipid carriers for enhanced batimastat delivery across the blood-brain barrier: an in vitro study for glioblastoma treatment.用于增强巴替麦司他透过血脑屏障递送的纳米结构脂质载体:一项针对胶质母细胞瘤治疗的体外研究
Drug Deliv Transl Res. 2025 Jan 6. doi: 10.1007/s13346-024-01775-8.
7
Revitalizing oral cancer research: Crispr-Cas9 technology the promise of genetic editing.重振口腔癌研究:CRISPR-Cas9技术带来的基因编辑希望。
Front Oncol. 2024 Jun 10;14:1383062. doi: 10.3389/fonc.2024.1383062. eCollection 2024.
8
Investigating Mutation as Underlying Cause of Familial Non-Medullary Thyroid Carcinoma.研究家族性非髓样甲状腺癌的潜在病因——突变。
Int J Mol Sci. 2024 Jan 26;25(3):1522. doi: 10.3390/ijms25031522.
9
CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review.CRISPR/Cas9介导的胶质母细胞瘤基因治疗:一项范围综述
Biomedicines. 2024 Jan 21;12(1):238. doi: 10.3390/biomedicines12010238.
基因组特征分析揭示了胃肠道神经内分泌癌中独特的突变特征和治疗意义。
Cancer Commun (Lond). 2022 Dec;42(12):1367-1386. doi: 10.1002/cac2.12372. Epub 2022 Oct 20.
4
LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma.LRP1B 突变与肝癌肿瘤突变负荷增加和预后不良相关。
Medicine (Baltimore). 2022 Jul 1;101(26):e29763. doi: 10.1097/MD.0000000000029763.
5
Paired guide RNA CRISPR-Cas9 screening for protein-coding genes and lncRNAs involved in transdifferentiation of human B-cells to macrophages.CRISPR-Cas9 靶向蛋白编码基因和长非编码 RNA 的双向导 RNA 筛选在人 B 细胞向巨噬细胞转分化中的作用
BMC Genomics. 2022 May 26;23(1):402. doi: 10.1186/s12864-022-08612-7.
6
Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway.下调低密度脂蛋白受体相关蛋白 1B(LRP1B)通过激活内质网应激信号通路抑制肝癌细胞的进展。
Bioengineered. 2022 Apr;13(4):9467-9481. doi: 10.1080/21655979.2022.2060778.
7
LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment.LRP1B是接受免疫检查点抑制剂治疗的肝癌患者肿瘤免疫原性和预后的潜在生物标志物。
J Hepatocell Carcinoma. 2022 Mar 22;9:203-220. doi: 10.2147/JHC.S348785. eCollection 2022.
8
CRISPR/Cas System and Factors Affecting Its Precision and Efficiency.CRISPR/Cas系统及其影响精度和效率的因素
Front Cell Dev Biol. 2021 Nov 24;9:761709. doi: 10.3389/fcell.2021.761709. eCollection 2021.
9
The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences.PRIDE 数据库资源在 2022 年:一个基于质谱的蛋白质组学证据的中心。
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. doi: 10.1093/nar/gkab1038.
10
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer.LRP1B表达作为卵巢癌中聚乙二醇化脂质体阿霉素治疗反应的一种潜在预测指标
Pathobiology. 2021;88(6):400-411. doi: 10.1159/000517372. Epub 2021 Oct 22.